Skip to main content

Table 5 Perceived concerns and barriers to prescribe PrEP among HIV physicians from Brazil and Mexico, 2020

From: Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey

  Total Brazil Mexico P valuea
(N = 481)
n (%)
(N = 339; 70.5%)
n (%)
(N = 142; 29.5%)
n (%)
 
Concerns (yes)
 Consistent access to PrEP medication 379 (78.6) 281 (82.9) 98 (68.3) <.001
 ARVb resistance in case of acute HIV infection or seroconversion 362 (75.1) 243 (71.7) 119 (83.2) <.01
 Risky behavior increasal 361 (74.9) 238 (70.2) 123 (86) <.001
 Users need to take a drug everyday 361 (74.9) 255 (75.2) 106 (74.1) .80
 Risk of ARV drug resistance 326 (67.6) 215 (63.4) 111 (77.6) <.01
 Severe adverse effects 270 (56) 179 (52.8) 91 (63.6) .03
 Mild adverse effects 204 (42.3) 131 (38.6) 73 (51.1) .01
 Limited availability of ARV for people living with HIV 266 (55.2) 177 (52.2) 89 (62.2) .04
 PrEP efficacy 177 (36.7) 112 (33) 65 (45.5) .01
Barriers (yes)
 Users have low PrEP knowledge 298 (62.0) 198 (58.4) 100 (70.4) .01
 Users have limited capacity for PrEP adherence 284 (59.0) 188 (55.5) 96 (67.6) .01
 Lack of professionals to prescribe PrEP 276 (57.4) 210 (62.0) 66 (46.5) <.01
 Limited time to discuss PrEP 171 (35.6) 111 (32.7) 60 (42.3) .05
 I have no knowledge about PrEP 165 (34.3) 89 (26.3) 76 (53.5) <.001
 I do not know where to refer a potential PrEP userc 81 (16.8) 81 (23.9) N/Ad
  1. aChi-square test
  2. bAntiretroviral
  3. cThis question was not asked in Mexico as PrEP is not current public policy
  4. dN/A Not applicable